Previous 10 | Next 10 |
2023-05-09 16:05:22 ET Arcturus Therapeutics press release ( NASDAQ: ARCT ): Q1 GAAP EPS of $1.87 beats by $1.46 . Revenue of $80.29M (+1432.3% Y/Y) beats by $30.83M . For further details see: Arcturus Therapeutics GAAP EPS of $1.87 beats by $1.46, revenu...
New Drug Application (NDA) for ARCT-154, a next generation COVID-19 vaccine, was submitted in Japan, leading to potential approval in 2023 $23.6 Million advanced for the manufacturing and supply of ARCT-154 ARCT-032 Phase 1 enrollment and administration completed successfully;...
2023-05-08 14:50:16 ET Arcturus Therapeutics ( NASDAQ: ARCT ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, after market close. The consensus EPS Estimate is -$0.01 and the consensus Revenue Estimate is $49.46M (vs. $5.24M last year). Over the last ...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare disease...
2023-04-11 13:03:15 ET Summary Arcturus is executing well, utilizing strategic partnerships with CSL and Meiji to de-risk its financial position. The company has reinforced its management team by appointing a CMO and CDO, bringing valuable experience to the company's pipeline deve...
2023-03-29 10:05:07 ET Gainers: Kodiak Sciences ( KOD ) +19% . Arcturus Therapeutics ( ARCT ) +16% . Erasca ( ERAS ) +15% . G Medical Innovations ( GMVD ) +15% . Atai Life Sciences ( ATAI ) +13% . Losers: ProQR The...
2023-03-28 19:02:04 ET Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2022 Earnings Conference Call March 28, 2023 04:30 PM ET Company Participants Neda Safarzadeh - IR Joseph Payne - President & CEO Andrew Sassine - CFO Padmanabh Chivukula - Chief Scienti...
2023-03-28 18:08:06 ET A combination of quarterly results beating on the top and bottom lines and an extension of its cash runway into 2026 has propelled Arcturus Therapeutics ( NASDAQ: ARCT ) ~21% higher in after-hours trading. The runway extension is due to the ...
2023-03-28 16:02:10 ET Arcturus Therapeutics press release ( NASDAQ: ARCT ): Q4 EPS of $4.33 may not be comparable to consensus of $1.23. Revenue of $160.29M (+2663.6% Y/Y) beats by $79.77M . For further details see: Arcturus Therapeutics EPS of $4.33, revenu...
$200 million upfront payment received in December 2022 from CSL collaboration Achieved $90 million in development milestones in March 2023 under CSL collaboration ARCT-154 Phase 3 COVID-19 booster trial enrollment completed in Japan Multiple patients enrolled in ARCT-8...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...